About
Kelderman holds a B.S. in applied sciences from Hogeschool Heerlen in the Netherlands, according to the company's proxy statement. He has been with Bio-Techne since 2018, when he became President of its Diagnostics and Genomics segment. Before that he led three businesses at Thermo Fisher Scientific, whose chief executive is Marc Casper, and worked as a senior segment leader at Becton Dickinson, which is led by Tom Polen. He also serves as a director of ConMed.
Whoo compiled this page from public sources: Bio-Techne 2025 proxy statement (SEC), Bio-Techne leadership transition filing, October 2023 (SEC), Bio-Techne quarterly report, September 2026 (SEC). It is not affiliated with or endorsed by Kim Kelderman. Are you Kim Kelderman? Claim this page, or write to [email protected] to correct or remove it. Last updated: 2026-11-18.
Want a page like this? Create yours from your résumé.
Experience
President and Chief Executive Officer — Bio-Techne
2024 – Present
- Appointed CEO and director effective February 1, 2024
- Led the segment now called Diagnostics and Spatial Biology
- Led three businesses at Thermo Fisher, including its genetic sciences platforms
- Senior segment leader for the Vacutainer blood tubes business at Becton Dickinson
President, Diagnostics and Genomics — Bio-Techne
2018 – 2024